Hematological Disorders

There has been limited progress in the approval of novel agents in MDS. It has been a long wait since the last approval of lenalidomide (Revlimid) – only approved for 5–10% (del 5q) MDS patients – was granted 13 years back. Since then, only two other companies, Celgene and Astex Pharma; could succeed in getting approvals for this rare disease. In April 2020, the US FDA approved Reblozyl (luspatercept-aamt; Celgene Corporation) for the treatment of anemia failing an ESA and requiring two or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk Myelodysplastic Syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/...